Karolina joined Parkwalk in 2021. She is responsible for new investments and managing existing portfolio companies in therapeutics, life sciences tools, and digital health.
Prior to Parkwalk, she spent nearly a decade building life sciences companies within the Cambridge Cluster. In 2018, she co-founded and successfully launched the first life sciences startup accelerator, with a portfolio of 20 early-stage ventures in Cambridge. She began her career as a scientist at a leading biopharmaceutical company, contributing to the development of a portfolio of biologics.
Karolina earned a PhD in biophysics/protein folding from the University of Cambridge and later conducted postdoctoral research in drug development at MedImmune/AstraZeneca. She also completed an Executive MBA in strategy and corporate transactions at HEC Paris.
She is a frequent speaker and panelist at various biotech conferences and events. Karolina sits on the boards of Ikarovec, Immutrin, Enhanc3D Genomics, Semarion, Qkine, and Psyomics.
